REFERENCES
1. Martin SS, Aday AW, Allen NB, et al. 2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2025;151:e41-660.
2. Jinson S, Zhang Z, Lancaster GI, Murphy AJ, Morgan PK. Iron, lipid peroxidation, and ferroptosis play pathogenic roles in atherosclerosis. Cardiovasc Res. 2025;121:44-61.
3. Gusdorf J, Faridi KF, Wang TY, et al. Inpatient outcomes for patients with peripheral artery disease hospitalized for acute myocardial infarction. J Am Heart Assoc. 2025;14:e040526.
4. Bookmeyer CHM, Correig FX, Masana L, Magni P, Yanes Ó, Vinaixa M. Advancing atherosclerosis research: the power of lipid imaging with MALDI-MSI. Atherosclerosis. 2025;403:119130.
5. Schaefer EJ, Asztalos BF, Vaisar T, et al. High density lipoprotein particle composition, functionality, deficiency, and atherosclerotic cardiovascular disease risk: a review. Curr Atheroscler Rep. 2025;27:62.
6. Botros M, Fadah K, Mukherjee D. The role of inflammatory response in the development of atherosclerosis, myocardial infarction, and remodeling. Vessel Plus. 2024;8:31.
7. Li H, Liu T, Shi X, et al. Mechanisms and therapeutic potential of pharmacological agents targeting inflammasomes. Biomed Pharmacother. 2025;189:118164.
8. Kraler S, Mueller C, Libby P, Bhatt DL. Acute coronary syndromes: mechanisms, challenges, and new opportunities. Eur Heart J. 2025;46:2866-89.
9. Ilyas I, Little PJ, Liu Z, et al. Mouse models of atherosclerosis in translational research. Trends Pharmacol Sci. 2022;43:920-39.
10. Jiang H, Liao Y, Zhu M, et al. Innovative atherosclerosis models: advancing pathophysiology and translational research. Research. 2025;8:0617.
11. Strijdhorst A, Vos WG, Bosmans LA, et al. Accelerated atherosclerosis associated with immune checkpoint inhibitors: a systematic review and meta-analysis of pre-clinical studies. Atherosclerosis. 2025;405:119219.
12. Wang R, Zhang H, Li S, et al. Current progress of in vitro vascular models on microfluidic chips. Biofabrication. 2025;17:022004.
13. Zhao Y, Qu H, Wang Y, Xiao W, Zhang Y, Shi D. Small rodent models of atherosclerosis. Biomed Pharmacother. 2020;129:110426.
14. Poznyak AV, Silaeva YY, Orekhov AN, Deykin AV. Animal models of human atherosclerosis: current progress. Braz J Med Biol Res. 2020;53:e9557.
15. Heo KS, Phan LP, Le NTT, Jin Y. Mechanistic insights and emerging therapeutic strategies targeting endothelial dysfunction in cardiovascular diseases. Arch Pharmacal Res. 2025;48:305-32.
16. Xu S, Ilyas I, Little PJ, et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies. Pharmacol Rev. 2021;73:924-67.
17. Oskroba A, Bartusik-Aebisher D, Myśliwiec A, et al. Photodynamic therapy and cardiovascular diseases. Int J Mol Sci. 2024;25:2974.
18. Mormone A, Tortorella G, Esposito F, et al. Advances in pharmacological approaches for managing hypercholesterolemia: a comprehensive overview of novel treatments. Biomedicines. 2024;12:432.
19. La Chica Lhoëst MT, Martinez A, Claudi L, et al. Mechanisms modulating foam cell formation in the arterial intima: exploring new therapeutic opportunities in atherosclerosis. Front Cardiovasc Med. 2024;11:1381520.
20. Carrizzo A, Izzo C, Forte M, et al. A novel promising frontier for human health: the beneficial effects of nutraceuticals in cardiovascular diseases. Int J Mol Sci. 2020;21:8706.
21. Wang X, Xie Z, Zhang J, et al. Interaction between lipid metabolism and macrophage polarization in atherosclerosis. iScience. 2025;28:112168.
22. Iliodromitis K, Seyfarth M, Balogh Z, Bogossian H, Iliodromitis E, Triposkiadis F. Anti-inflammatory interventions in coronary artery disease: antipodal responses requiring targeted therapeutic strategies. Basic Res Cardiol. 2025;120:597-618.
23. Chen R, Zhou Z, Song Z, et al. Tangzhiqing exacerbates oxidized low-density lipoprotein-induced cell pyroptosis through activation of NLRP3 inflammasome in human umbilical vein endothelial cells. Cell Biol Int. 2025;49:1173-83.
24. Lin L, Deng KQ, Chen Z, et al. Lipoprotein(a) distribution and its association with carotid arteriopathy in the Chinese population. Atherosclerosis. 2023;372:1-9.
25. Wang Z, Ye M, Zhang XJ, et al. Impact of NAFLD and its pharmacotherapy on lipid profile and CVD. Atherosclerosis. 2022;355:30-44.
26. Kwon H, Ryu JC, Cha JK, et al. Low-density lipoprotein cholesterol level, the lower the better? Analysis of Korean patients in the treat stroke to target trial. J Stroke. 2025;27:228-36.
27. Tian Y, Zong Y, Pang Y, et al. Platelets and diseases: signal transduction and advances in targeted therapy. Signal Transduct Target Ther. 2025;10:159.
28. Rauch PJ, Gopakumar J, Silver AJ, et al. Loss-of-function mutations in Dnmt3a and Tet2 lead to accelerated atherosclerosis and concordant macrophage phenotypes. Nat Cardiovasc Res. 2023;2:805-18.
29. Getz GS, Reardon CA. Do the Apoe-/- and Ldlr-/- mice yield the same insight on atherogenesis? Arterioscler Thromb Vasc Biol. 2016;36:1734-41.
30. Emini Veseli B, Perrotta P, De Meyer GRA, et al. Animal models of atherosclerosis. Eur J Pharmacol. 2017;816:3-13.
31. Zhang Y, Ren D, Liu Y, et al. Mechanism of red yeast rice in the improvement of atherosclerosis in apolipoprotein E-deficient mice explored through metabolomics combined with serum pharmacochemistry and network pharmacology. Plant Foods Hum Nutr. 2025;80:140.
32. Rosenfeld ME, Polinsky P, Virmani R, Kauser K, Rubanyi G, Schwartz SM. Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler Thromb Vasc Biol. 2000;20:2587-92.
33. van Leeuwen M, Gijbels MJ, Duijvestijn A, et al. Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesions in LDLR-/- mice. Arterioscler Thromb Vasc Biol. 2008;28:84-9.
34. Getz GS, Reardon CA. PCSK9 and lipid metabolism and atherosclerosis: animal models. Vessel Plus. 2021;5:17.
35. Meyrelles SS, Peotta VA, Pereira TM, Vasquez EC. Endothelial dysfunction in the apolipoprotein E-deficient mouse: insights into the influence of diet, gender and aging. Lipids Health Dis. 2011;10:211.
36. Nieswandt B, Aktas B, Moers A, Sachs UJ. Platelets in atherothrombosis: lessons from mouse models. J Thromb Haemost. 2005;3:1725-36.
37. Inia JA, van Nieuwkoop-van Straalen A, Jukema JW, et al. Efficacy of a novel PCSK9 inhibitory peptide alone and with evinacumab in a mouse model of atherosclerosis. J Lipid Res. 2025;66:100753.
38. Ruotsalainen AK, Lappalainen JP, Heiskanen E, et al. Nuclear factor E2-related factor 2 deficiency impairs atherosclerotic lesion development but promotes features of plaque instability in hypercholesterolaemic mice. Cardiovasc Res. 2019;115:243-54.
39. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA. 1992;89:4471-5.
40. Liu D, Mai D, Jahn AN, et al. APOE protects against severe infection with Mycobacterium tuberculosis by restraining production of neutrophil extracellular traps. PLoS Pathog. 2025;21:e1013267.
41. Murphy AJ, Akhtari M, Tolani S, et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J Clin Invest. 2011;121:4138-49.
42. Johnson J, Carson K, Williams H, et al. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment. Circulation. 2005;111:1422-30.
43. Oppi S, Lüscher TF, Stein S. Mouse models for atherosclerosis research-which is my line? Front Cardiovasc Med. 2019;6:46.
44. Fernandez DM, Giannarelli C. Immune cell profiling in atherosclerosis: role in research and precision medicine. Nat Rev Cardiol. 2022;19:43-58.
45. Schroeter MR, Humboldt T, Schäfer K, Konstantinides S. Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilisation and recruitment in apolipoprotein E knockout mice. Atherosclerosis. 2009;205:63-73.
46. Peng C, Li J, Chen Y, et al. PCSK9 aggravated carotid artery stenosis in ApoE-/- mice by promoting the expression of tissue factors in endothelial cells via the TLR4/NF-κB pathway. Biochem Pharmacol. 2024;225:116314.
47. Guo X, Wang L, Xia X, Wang P, Li X. Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice. Biomed Pharmacother. 2019;109:1445-53.
48. Di Marco E, Gray SP, Chew P, et al. Pharmacological inhibition of NOX reduces atherosclerotic lesions, vascular ROS and immune-inflammatory responses in diabetic Apoe-/- mice. Diabetologia. 2014;57:633-42.
49. Jongejan YK, Eikenboom JCJ, Gijbels MJJ, Berbée JFP, van Vlijmen BJM. Atherothrombosis model by silencing of protein C in APOE*3-Leiden.CETP transgenic mice. J Thromb Thrombolysis. 2021;52:715-9.
50. Westerterp M, van der Hoogt CC, de Haan W, et al. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arterioscler Thromb Vasc Biol. 2006;26:2552-9.
51. Paalvast Y, Zhou E, Rozendaal YJW, et al. A systems analysis of phenotype heterogeneity in APOE*3Leiden.CETP mice induced by long-term high-fat high-cholesterol diet feeding. Nutrients. 2022;14:4936.
52. Paalvast Y, Gerding A, Wang Y, et al. Male apoE*3-Leiden.CETP mice on high-fat high-cholesterol diet exhibit a biphasic dyslipidemic response, mimicking the changes in plasma lipids observed through life in men. Physiol Rep. 2017;5:e13376.
53. Kong YY, Li GQ, Zhang WJ, et al. Nicotinamide phosphoribosyltransferase aggravates inflammation and promotes atherosclerosis in ApoE knockout mice. Acta Pharmacol Sin. 2019;40:1184-92.
54. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest. 1994;93:1885-93.
55. Schmidt HM, Jarrett KE, de Aguiar Vallim TQ, Tarling EJ. Pathways and molecular mechanisms governing LDL receptor regulation. Circ Res. 2025;136:902-19.
56. Hartvigsen K, Binder CJ, Hansen LF, et al. A diet-induced hypercholesterolemic murine model to study atherogenesis without obesity and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2007;27:878-85.
57. Hoekstra M, Van Eck M. HDL is redundant for adrenal steroidogenesis in LDLR knockout mice with a human-like lipoprotein profile. J Lipid Res. 2016;57:631-7.
58. Burke AC, Telford DE, Huff MW. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 2019;30:1-9.
59. Wouters K, Shiri-sverdlov R, Van Gorp PJ, Van Bilsen M, Hofker MH. Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice. Clin Chem Lab Med. 2005;43:470-9.
60. Ibrahim S, Hartgers ML, Reeskamp LF, et al. LDLR variant classification for improved cardiovascular risk prediction in familial hypercholesterolemia. Atherosclerosis. 2024;397:117610.
61. Stankov S, Cuchel M. Gene editing for dyslipidemias: new tools to “cut” lipids. Atherosclerosis. 2023;368:14-24.
62. Véniant MM, Zlot CH, Walzem RL, et al. Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice. J Clin Investig. 1998;102:1559-68.
63. Calara F, Silvestre M, Casanada F, Yuan N, Napoli C, Palinski W. Spontaneous plaque rupture and secondary thrombosis in apolipoprotein E-deficient and LDL receptor-deficient mice. J. Pathol. 2001;195:257-63.
64. Hellberg S, Sippola S, Liljenbäck H, et al. Effects of atorvastatin and diet interventions on atherosclerotic plaque inflammation and [18F]FDG uptake in Ldlr-/-Apob mice. Atherosclerosis. 2017;263:369-76.
65. Bhakta S, Kodama H, Mimaki M, Tsukahara T. Restoration of genetic code in macular mouse fibroblasts via APOBEC1-mediated RNA editing. Biomolecules. 2025;15:136.
66. Miyajima C, Iwaki T, Umemura K, Ploplis VA, Castellino FJ. Characterization of atherosclerosis formation in a murine model of type IIa human familial hypercholesterolemia. Biomed Res Int. 2018;2018:1878964.
67. Dutta R, Singh U, Li T, Fornage M, Teng B. Hepatic gene expression profiling reveals perturbed calcium signaling in a mouse model lacking both LDL receptor and Apobec1 genes. Atherosclerosis. 2003;169:51-62.
68. Shao B, Shimizu-albergine M, Kramer F, et al. A targeted proteomics method for quantifying plasma apolipoprotein kinetics in individual mice using stable isotope labeling. J Lipid Res. 2024;65:100531.
69. Basu D, Bornfeldt KE. Hypertriglyceridemia and atherosclerosis: using human research to guide mechanistic studies in animal models. Front Endocrinol. 2020;11:504.
70. Hajighasemi S, Mahdavi Gorabi A, Bianconi V, et al. A review of gene- and cell-based therapies for familial hypercholesterolemia. Pharmacol Res. 2019;143:119-32.
71. Getz GS, Reardon CA. Insights from murine studies on the site specificity of atherosclerosis. Int J Mol Sci. 2024;25:6375.
72. Ajoolabady A, Pratico D, Mazidi M, et al. PCSK9 in metabolism and diseases. Metabolism. 2025;163:156064.
73. Shamsuzzaman S, Deaton RA, Salamon A, et al. Novel mouse model of myocardial infarction, plaque rupture, and stroke shows improved survival with myeloperoxidase inhibition. Circulation. 2024;150:687-705.
74. Liang Y, Liu J, Zhang C, et al. Integrating serum pharmacochemistry and metabolomics to reveal the potential effective ingredients and mechanism of Huangqi Chifeng Tang intervening carotid atherosclerosis. J Ethnopharmacol. 2025;351:120065.
75. Gomes D, Wang S, Goodspeed L, et al. Comparison between genetic and pharmaceutical disruption of Ldlr expression for the development of atherosclerosis. J Lipid Res. 2022;63:100174.
76. Bjørklund MM, Hollensen AK, Hagensen MK, et al. Induction of atherosclerosis in mice and hamsters without germline genetic engineering. Circ Res. 2014;114:1684-9.
77. Park C, Baek KI, Hung R, et al. Disturbed flow induces reprogramming of endothelial cells to immune-like and foam cells under hypercholesterolaemia during atherogenesis. Cardiovasc Res. 2025;121:2679-99.
78. Zhou X, Kuenne C, Günther S, et al. Nuclear eNOS interacts with and S-nitrosates ADAR1 to modulate type I interferon signaling and endothelial function. Circulation. 2025;152:1781-99.
79. Jiang D, Liu H, Zhu G, et al. Endothelial PHACTR1 promotes endothelial activation and atherosclerosis by repressing PPARγ activity under disturbed flow in mice. Arterioscler Thromb Vasc Biol. 2023;43:8.
80. Mitra R, Qiao J, Madhavan S, et al. The comparative effects of high fat diet or disturbed blood flow on glycocalyx integrity and vascular inflammation. Transl Med Commun. 2018;3:10.
81. Nam D, Ni C, Rezvan A, et al. Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis. Am J Physiol Heart Circ Physiol. 2009;297:H1535-43.
82. Dib L, Koneva LA, Edsfeldt A, et al. Lipid-associated macrophages transition to an inflammatory state in human atherosclerosis, increasing the risk of cerebrovascular complications. Nat Cardiovasc Res. 2023;2:656-72.
83. Cho M, Hwang JS, Kim KR, Kim JK. Wall shear stress (WSS) analysis in atherosclerosis in partial ligated apolipoprotein E knockout mouse model through computational fluid dynamics (CFD). Int J Mol Sci. 2024;25:9877.
84. Chien C, Li JY, Chien Y, et al. METTL3-dependent N6-methyladenosine RNA modification mediates the atherogenic inflammatory cascades in vascular endothelium. Proc Natl Acad Sci USA. 2021;118:e2025070118.
85. Hu S, Liu Y, You T, et al. Vascular semaphorin 7A upregulation by disturbed flow promotes atherosclerosis through endothelial β1 integrin. Arterioscler Thromb Vasc Biol. 2018;38:335-43.
86. Pinos I, Coronel J, Albakri A, et al. β-carotene accelerates the resolution of atherosclerosis in mice. eLife. 2024;12:RP87430.
87. Chen Y, Johnson SM, Burr SD, et al. Absence of the intracellular lipolytic inhibitor G0S2 enhances intravascular triglyceride clearance and abolishes diet-induced hypertriglyceridemia. J Clin Investig. 2025;135:e181754.
88. Basu D, Hu Y, Huggins L, et al. Novel reversible model of atherosclerosis and regression using oligonucleotide regulation of the LDL receptor. Circ Res. 2018;122:560-7.
89. Josefs T, Basu D, Vaisar T, et al. Atherosclerosis regression and cholesterol efflux in hypertriglyceridemic mice. Circ Res. 2021;128:690-705.
90. Bashore AC, Liu M, Key CC, et al. Targeted deletion of hepatocyte Abca1 increases plasma HDL (high-density lipoprotein) reverse cholesterol transport via the LDL (low-density lipoprotein) receptor. Arterioscler Thromb Vasc Biol. 2019;39:1747-61.
91. Burr SD, Chen Y, Hartley CP, Zhao X, Liu J. Replacement of saturated fatty acids with linoleic acid in western diet attenuates atherosclerosis in a mouse model with inducible ablation of hepatic LDL receptor. Sci Rep. 2023;13:16832.
92. Mullick AE, Fu W, Graham MJ, et al. Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice. J Lipid Res. 2011;52:885-96.
93. Pennig J, Scherrer P, Gissler MC, et al. Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice. Sci Rep. 2019;9:17937.
94. Ansari A, Yadav PK, Zhou L, et al. Casz1 and Znf101/Zfp961 differentially regulate apolipoproteins A1 and B, alter plasma lipoproteins, and reduce atherosclerosis. JCI Insight. 2025;10:e182260.
95. Yurtseven E, Ural D, Baysal K, Tokgözoğlu L. An update on the role of PCSK9 in atherosclerosis. J Atheroscler Thromb. 2020;27:909-18.
96. Roche-molina M, Sanz-rosa D, Cruz FM, et al. Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9. Arterioscler Thromb Vasc Biol. 2015;35:50-9.
97. Caruana V, Giles BH, Kukolj N, Juran R, Baglole CJ, Mann KK. Chronic exposure to E-cigarette aerosols potentiates atherosclerosis in a sex-dependent manner. Toxicol Appl Pharmacol. 2024;492:117095.
98. Buchmann GK, Schürmann C, Warwick T, et al. Deletion of NoxO1 limits atherosclerosis development in female mice. Redox Biol. 2020;37:101713.
99. Jia M, Li Q, Guo J, et al. Deletion of BACH1 attenuates atherosclerosis by reducing endothelial inflammation. Circ Res. 2022;130:1038-55.
100. Cansby E, Magnusson E, Nuñez-Durán E, et al. STK25 regulates cardiovascular disease progression in a mouse model of hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2018;38:1723-37.
101. Huang L, Chambliss KL, Gao X, et al. SR-B1 drives endothelial cell LDL transcytosis via DOCK4 to promote atherosclerosis. Nature. 2019;569:565-9.
102. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 1996;271:518-20.
103. Kaabia Z, Poirier J, Moughaizel M, et al. Plasma lipidomic analysis reveals strong similarities between lipid fingerprints in human, hamster and mouse compared to other animal species. Sci Rep. 2018;8:15893.
104. Ellis ECS, Nauglers S, Parini P, et al. Mice with chimeric livers are an improved model for human lipoprotein metabolism. PLoS ONE. 2013;8:e78550.
105. Sun T, Chen M, Shen H, et al. Predictive value of LDL/HDL ratio in coronary atherosclerotic heart disease. BMC Cardiovasc Disord. 2022;22:273.
106. Sari G, Meester EJ, Van Der Zee LC, et al. A mouse model of humanized liver shows a human-like lipid profile, but does not form atherosclerotic plaque after western type diet. Biochem Biophys Res Commun. 2020;524:510-5.
107. Schwartz SM, Galis ZS, Rosenfeld ME, Falk E. Plaque rupture in humans and mice. Arterioscler Thromb Vasc Biol. 2007;27:705-13.
108. Marino A, Zhang Y, Rubinelli L, Riemma MA, Ip JE, Di Lorenzo A. Pressure overload leads to coronary plaque formation, progression, and myocardial events in ApoE-/- mice. JCI Insight. 2019;4:e128220.
109. Gisterå A, Ketelhuth DF, Malin SG, Hansson GK. Animal models of atherosclerosis-supportive notes and tricks of the trade. Circ Res. 2022;130:1869-87.
110. Wan M, Pan S, Shan B, et al. Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment. Mol Cancer. 2025;24:61.
111. Checkouri E, Blanchard V, Meilhac O. Macrophages in atherosclerosis, first or second row players? Biomedicines. 2021;9:1214.
112. Ebert ML, Schmidt VF, Pfaff L, Von Thaden A, Kimm MA, Wildgruber M. Animal models of neointimal hyperplasia and restenosis. JACC Basic Transl Sci. 2021;6:900-17.
113. Hansson GK, Heistad DD. Two views on plaque rupture. Arterioscler Thromb Vasc Biol. 2007;27:697.
114. Rosenson RS, Brewer HB, Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125:1905-19.
115. Schmidt AF, Hunt NB, Gordillo-marañón M, et al. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nat Commun. 2021;12:5640.
116. Aizaz M, Bierens J, Gijbels MJ, et al. Differentiation of atherosclerotic carotid plaque components with dual-energy computed tomography. Investig Radiol. 2025;60:508-16.
117. Delwarde C, Aikawa M. Novel mouse model of late-stage coronary atherosclerosis with features of plaque rupture and stroke. Circulation. 2024;150:706-9.
118. Golforoush P, Yellon DM, Davidson SM. Mouse models of atherosclerosis and their suitability for the study of myocardial infarction. Basic Res Cardiol. 2020;115:73.
120. Alebna PL, Ambrosio M, Martin M, et al. Association of Lipoprotein(a) with cardiovascular events among individuals with autoimmune conditions. Atherosclerosis. 2025;406:119244.
121. Kunimura A, Amano T, Uetani T, et al. Prognostic impact of concurrence of metabolic syndrome and chronic kidney disease in patients undergoing coronary intervention: involvement of coronary plaque composition. J Cardiol. 2013;61:189-95.
122. Reiss AB, Glass DS, Voloshyna I, Glass AD, Kasselman LJ, De Leon J. Obesity and atherosclerosis: the exosome link. Vessel Plus. 2020;4:19.
123. Von Scheidt M, Zhao Y, Kurt Z, et al. Applications and limitations of mouse models for understanding human atherosclerosis. Cell Metab. 2017;25:248-61.
124. Zhang Y, Cheng Z, Hong L, et al. Apolipoprotein E (ApoE) orchestrates adipose tissue inflammation and metabolic disorders through NLRP3 inflammasome. Mol Biomed. 2023;4:47.
125. Cefalu WT. Animal models of type 2 diabetes: clinical presentation and pathophysiological relevance to the human condition. ILAR J. 2006;47:186-98.
126. Daugherty A, Sawada H, Sheppard MB, Lu HS. Angiotensinogen as a therapeutic target for cardiovascular and metabolic diseases. Arterioscler Thromb Vasc Biol. 2024;44:1021-30.
127. Lee YT, Lin HY, Chan YWF, et al. Mouse models of atherosclerosis: a historical perspective and recent advances. Lipids Health Dis. 2017;16:12.
128. Wang J, Shan S, Lyu A, Wan Y, Zhang J. A novel model of myocardial infarction based on atherosclerosis in mice. Biochem Biophys Res Commun. 2021;576:100-7.
129. Bimal T, Ayyalu T, Safarova MS, et al. Inadequate response to PCSK9 inhibitors. JACC Case Rep. 2025;30:103696.
130. Tardif JC, Pfeffer MA, Kouz S, et al. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial. Eur Heart J. 2022;43:3947-56.
131. Puri R, Nissen SE, Arsenault BJ, et al. Effect of C-reactive protein on lipoprotein(a)-associated cardiovascular risk in optimally treated patients with high-risk vascular disease: a prespecified secondary analysis of the ACCELERATE trial. JAMA Cardiol. 2020;5:1136.
132. Centa M, Ketelhuth DF, Malin S, Gisterå A. Quantification of atherosclerosis in mice. J Vis Exp. 2019;148:e59828.
133. Barettino A, González-Gómez C, Gonzalo P, et al. Endothelial YAP/TAZ activation promotes atherosclerosis in a mouse model of Hutchinson-Gilford progeria syndrome. J Clin Investig. 2024;134:e173448.
134. Hamczyk MR, Nevado RM, Gonzalo P, et al. Endothelial-to-mesenchymal transition contributes to accelerated atherosclerosis in hutchinson-gilford progeria syndrome. Circulation. 2024;150:1612-30.
135. Damluji AA, Nanna MG, Mason P, et al. Coronary artery revascularization in the older adult population: a scientific statement from the American Heart Association. Circulation. 2025;152:25.
136. Jin KT, Du WL, Lan HR, et al. Development of humanized mouse with patient‐derived xenografts for cancer immunotherapy studies: a comprehensive review. Cancer Sci. 2021;112:2592-606.
